VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent

Expands VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio to
Enable Breakthrough Readouts of Cathepsin-K Biomarkers in Research and Drug
Development

BEDFORD, Mass., July 7 /PRNewswire/ -- VisEn Medical Inc., a leader in
fluorescence in vivo imaging from research through medicine, announced today
the commercial launch of its new Cat-K FAST(TM) imaging agent for measuring
and monitoring Cathepsin K activity associated with disease progression and
therapeutic response in vivo. Cathepsin K expression is well known as a key
biomarker and therapeutic target in a range of bone-related diseases,
including cancer metastasis to bone, as well as in atherosclerosis. The new
Cat-K FAST(TM) agent is expected to significantly expand research and enhance
drug development in these areas by enabling real time imaging of Cat-K
activity.

Cat-K FAST(TM) represents an additional protease-sensing agent developed and
commercially launched based on VisEn's new FAST ("Fluorescent Activatable
Sensor Technology") in vivo agent platform. FAST agents are based on
high-performance, activatable smaller molecules that combine biomarker
specificity with optimized biocompatibility and pharmacokinetics for precise
measurement and monitoring of key disease biomarkers in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to
provide the industry's broadest and most robust range of biologically-specific
imaging readouts in vivo. VisEn now offers over 25 different fluorescence
molecular agents for imaging key disease-associated biologic targets,
processes and pathways. VisEn agent brands include ProSense(R),
IntegriSense(TM), AngioSense(TM), OsteoSense(R) and MMPSense(TM). VisEn also
offers its specialized in vivo agent labeling platforms, including its
proprietary VivoTag(R) fluorescence labeling dyes for custom agent
development, and its NanoSpark(R) labeling nanoparticles, all designed and
optimized specifically for superior biocompatibility, brightness, stability
and performance in in vivo imaging. All VisEn agents and labels, including
the new Cat-K FAST(TM) agent, are designed for in vivo biomarker
quantification using VisEn's Fluorescence Molecular Tomography (FMT(TM))
imaging systems, or for general use along with other non-quantitative
fluorescence in vivo imaging systems. VisEn agents are also designed to
enable in vitro biomarker readouts in cells and tissues using standard
fluorescence microscopy and cellular-based imaging systems. With a focus on
translational research and results, all of VisEn's technologies are designed
to generate translational data linking pre-clinical research into clinical
medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence
Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging
Systems, provide robust fluorescence molecular imaging performance in
identifying, characterizing and quantifying ranges of disease biomarkers and
therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by
leading research institutions and pharmaceutical companies worldwide in
applications including cancer research, inflammation, cardiovascular, skeletal
and pulmonary disease. The Company also works with large pharmaceutical
partners to design ranges of tailored molecular imaging agents and
applications designed for their specific pre-clinical and clinical research
areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.

Robert Sandler, VP, Marketing, VisEn Medical Inc., +1-647-350-1881,
+1-416-274-8166, rsandler@visenmedical.com; or Peter Steinerman, Principal,
Steinerman Biomedical Comm., +1-516-374-3031, +1-516-641-8959,
PRSteinerman@aol.com